EGFR and lung adenocarcinoma: According to the World Health Organization, lung adenocarcinoma is the major causes of mortality.[1] Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) as the first-line therapy were used for treatment of EGFR-mutant lung adenocarcinoma for more than 10 years.